X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3369) 3369
Publication (562) 562
Newsletter (111) 111
Book Review (45) 45
Book Chapter (25) 25
Conference Proceeding (15) 15
Newspaper Article (13) 13
Dissertation (5) 5
Transcript (2) 2
Book / eBook (1) 1
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2158) 2158
humans (1878) 1878
animals (1812) 1812
sphingosine - analogs & derivatives (1661) 1661
sphingosine (1350) 1350
sphingosine 1-phosphate (1111) 1111
mice (856) 856
male (801) 801
phosphates (767) 767
fingolimod hydrochloride (759) 759
sphingosine-1-phosphate (725) 725
female (615) 615
lipids (578) 578
apoptosis (561) 561
propylene glycols - therapeutic use (560) 560
sphingosine - pharmacology (539) 539
fty720 (516) 516
pharmacology & pharmacy (511) 511
cell biology (510) 510
immunosuppressive agents - therapeutic use (507) 507
sphingosine - therapeutic use (498) 498
sphingosine - metabolism (490) 490
biochemistry & molecular biology (486) 486
rats (437) 437
article (423) 423
sphingolipids (422) 422
analysis (421) 421
cancer (418) 418
lysophospholipids - metabolism (414) 414
immunology (402) 402
multiple sclerosis (390) 390
signal transduction (378) 378
ceramide (377) 377
inflammation (375) 375
kinases (356) 356
sphingosine kinase (353) 353
research (332) 332
physiological aspects (331) 331
receptors, lysosphingolipid - metabolism (328) 328
activation (315) 315
proteins (308) 308
mice, inbred c57bl (296) 296
neurosciences (296) 296
oncology (290) 290
cells (286) 286
disease models, animal (281) 281
expression (280) 280
health aspects (271) 271
propylene glycols - pharmacology (268) 268
fingolimod (253) 253
adult (249) 249
phosphotransferases - metabolism (244) 244
cells, cultured (242) 242
research article (241) 241
gene expression (234) 234
metabolism (232) 232
medicine (231) 231
multidisciplinary sciences (231) 231
middle aged (223) 223
rodents (221) 221
transplantation (220) 220
apoptosis - drug effects (214) 214
cell line, tumor (212) 212
signal transduction - drug effects (211) 211
enzymes (209) 209
care and treatment (207) 207
multiple sclerosis - drug therapy (207) 207
immunosuppressive agents - pharmacology (200) 200
science (196) 196
clinical neurology (195) 195
phosphorylation (194) 194
oral fingolimod (192) 192
in-vivo (189) 189
surgery (187) 187
lymphocytes (177) 177
dose-response relationship, drug (175) 175
medicine, research & experimental (171) 171
lysophospholipids - pharmacology (169) 169
inhibition (166) 166
sphingolipids - metabolism (165) 165
multiple-sclerosis (163) 163
receptors (162) 162
protein-coupled receptor (159) 159
angiogenesis (157) 157
lymphocyte egress (156) 156
biology (154) 154
physiology (153) 153
development and progression (150) 150
phosphotransferases - antagonists & inhibitors (150) 150
cytokines (147) 147
biophysics (144) 144
neurology (144) 144
s1p (142) 142
ceramides - metabolism (141) 141
sphingosine kinase 1 (140) 140
disease (139) 139
endothelial-cells (139) 139
biochemistry (136) 136
treatment outcome (136) 136
endothelium (134) 134
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3445) 3445
Japanese (15) 15
French (10) 10
German (10) 10
Chinese (8) 8
Hungarian (7) 7
Spanish (6) 6
Russian (4) 4
Finnish (2) 2
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLOS ONE, ISSN 1932-6203, 10/2013, Volume 8, Issue 10
In the present study, we investigated the therapeutic potential of a selective S1P(1) receptor modulator, ponesimod, to protect and reverse autoimmune diabetes... 
B-CELLS | RELAPSING MULTIPLE-SCLEROSIS | NOD MICE | ORAL FINGOLIMOD | GLUTAMIC-ACID DECARBOXYLASE | LYMPHOID ORGANS | FTY720 | TOLERANCE | MULTIDISCIPLINARY SCIENCES | REGULATORY T-CELLS | SPHINGOSINE 1-PHOSPHATE
Journal Article
PHARMACOLOGICAL REVIEWS, ISSN 0031-6997, 06/2008, Volume 60, Issue 2, pp. 181 - 195
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabolite involved in many critical cellular processes including proliferation, survival, and... 
BREAST-CANCER CELLS | SPHINGOSINE 1-PHOSPHATE RECEPTOR | KINASE INHIBITOR SUPPRESSES | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | PROTEIN-COUPLED RECEPTOR | GENE-DEFICIENT MICE | PHARMACOLOGY & PHARMACY | RANDOMIZED CONTROLLED-TRIAL | MAST-CELL DEGRANULATION | NOVO RENAL-TRANSPLANTATION | ENDOTHELIAL BARRIER FUNCTION | Hypersensitivity - enzymology | Sulfhydryl Compounds - pharmacology | Apoptosis - drug effects | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Hypersensitivity - drug therapy | Lysophospholipids - immunology | Propylene Glycols - therapeutic use | Antineoplastic Agents - pharmacology | Immunosuppressive Agents - pharmacology | Propylene Glycols - pharmacology | Multiple Sclerosis - enzymology | Signal Transduction | Sphingosine - physiology | Antibodies, Monoclonal - pharmacology | Fingolimod Hydrochloride | Neoplasms - enzymology | Receptors, Lysosphingolipid - physiology | Sphingosine - immunology | Neoplasms - drug therapy | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Sphingosine - pharmacology | Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors | Sphingosine - analogs & derivatives | Animals | Receptors, Lysosphingolipid - agonists | Sphingosine - therapeutic use | Sulfhydryl Compounds - therapeutic use | Enzyme Activation | Lysophospholipids - physiology | Multiple Sclerosis - drug therapy
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 152, Issue 2, pp. 374 - 388.e4
Insights into the pathogenesis of inflammatory bowel diseases (IBDs) have provided important information for the development of therapeutics. Levels of... 
Gastroenterology and Hepatology | Crohn’s Disease | Therapy | Intestine | Ulcerative Colitis | Crohn's Disease | ANTIINTERFERON-GAMMA ANTIBODY | NK-T-CELLS | PATHOGENIC T(H)17 CELLS | INNATE LYMPHOID-CELLS | SEVERE CROHNS-DISEASE | INTESTINAL EPITHELIAL-CELLS | GROWTH-FACTOR-BETA | HELPER 17 CELLS | JANUS KINASE INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | GENOME-WIDE ASSOCIATION | Inflammatory Bowel Diseases - drug therapy | Transforming Growth Factor beta - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Oligonucleotides - therapeutic use | Signal Transduction | Humans | Inflammatory Bowel Diseases - immunology | Antibodies, Monoclonal - therapeutic use | Sphingosine - immunology | Molecular Targeted Therapy | Ustekinumab - therapeutic use | Interleukin-23 - immunology | Lysophospholipids - immunology | Sphingosine - analogs & derivatives | Smad7 Protein - immunology | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Th17 Cells - immunology | Janus Kinases - immunology | Pyrroles - therapeutic use | Cytokines - immunology | Inflammatory bowel diseases | Care and treatment | Colitis | Interleukins | Therapeutics | Homeopathy | Materia medica and therapeutics | Medical research | Biological response modifiers | Transforming growth factors | Sulfates | Dextran | Medicine, Experimental | Interferon | Ulcerative colitis | ulcerative colitis | intestine | therapy | Crohn’s disease
Journal Article
Journal Article
Lancet Neurology, ISSN 1474-4422, 2012, Volume 11, Issue 5, pp. 420 - 428
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 11/2009, Volume 158, Issue 5, pp. 1173 - 1182
FTY720 (fingolimod) is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was highly effective in Phase II clinical trials for Multiple... 
Multiple Sclerosis | infection | FTY720 (fingolimod) | S1P (sphingosine 1-phosphate) | autoimmunity | immunotherapy | central nervous system | S1P (sphingosine 1‐phosphate) | Autoimmunity | Infection | Multiple sclerosis | Immunotherapy | Central nervous system | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | T-CELL SUBSETS | IMMUNOMODULATOR FTY720 | PHOSPHORYLATION | AGONISM IMPAIRS | SPHINGOSINE 1-PHOSPHATE RECEPTOR-1 | S1P | ENDOTHELIAL-CELLS | EGRESS | PHARMACOLOGY & PHARMACY | SECONDARY LYMPHOID-TISSUES | T-Lymphocytes - physiology | Phosphorylation | Receptors, Lysosphingolipid - antagonists & inhibitors | Lymph Nodes - pathology | Humans | Astrocytes - pathology | Encephalomyelitis, Autoimmune, Experimental - immunology | Astrocytes - immunology | Propylene Glycols - therapeutic use | Receptors, Lysosphingolipid - genetics | Propylene Glycols - pharmacology | Sphingosine - physiology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Fingolimod Hydrochloride | Phosphotransferases (Alcohol Group Acceptor) - genetics | Receptors, Lysosphingolipid - physiology | Inflammation - immunology | Lymph Nodes - immunology | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Brain - drug effects | Sphingosine - pharmacology | Sphingosine - analogs & derivatives | Animals | Gap Junctions - physiology | Immune System - drug effects | Multiple Sclerosis - immunology | Sphingosine - therapeutic use | Lysophospholipids - physiology | Multiple Sclerosis - drug therapy | Review
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2010, Volume 362, Issue 5, pp. 402 - 415
Journal Article
Nature, ISSN 0028-0836, 2013, Volume 502, Issue 7471, pp. 327 - 332
Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature... 
OLIGODENDROCYTE DIFFERENTIATION | PROGENITOR CELLS | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | MUSCARINIC RECEPTOR SUBTYPES | THYROID-HORMONE | MYELIN REPAIR | MULTIDISCIPLINARY SCIENCES | EMBRYONIC STEM-CELLS | SPINAL-CORD | CENTRAL-NERVOUS-SYSTEM | PRECURSOR CELLS | Cuprizone - therapeutic use | Oligodendroglia - metabolism | Optic Nerve - cytology | Recurrence | Antiparkinson Agents - pharmacology | Coculture Techniques | Myelin Sheath - drug effects | Receptor, Muscarinic M1 - antagonists & inhibitors | Stem Cells - cytology | Myelin Proteolipid Protein - pharmacology | Myelin Sheath - metabolism | Antiparkinson Agents - therapeutic use | Oligodendroglia - drug effects | Cuprizone - pharmacology | Encephalomyelitis, Autoimmune, Experimental - chemically induced | Propylene Glycols - therapeutic use | Immune System - immunology | Female | Oligodendroglia - cytology | Benztropine - therapeutic use | Propylene Glycols - pharmacology | Encephalomyelitis, Autoimmune, Experimental - pathology | Myelin Sheath - pathology | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Mice, Inbred C57BL | Receptor, Muscarinic M3 - metabolism | Fingolimod Hydrochloride | Rats | Receptor, Muscarinic M3 - antagonists & inhibitors | Oligodendroglia - pathology | Sphingosine - pharmacology | Regeneration - drug effects | Sphingosine - analogs & derivatives | Animals | Cell Differentiation - drug effects | Models, Biological | Immune System - drug effects | Multiple Sclerosis - pathology | Stem Cells - drug effects | Sphingosine - therapeutic use | Mice | Benztropine - pharmacology | Receptor, Muscarinic M1 - metabolism | Multiple Sclerosis - drug therapy | Benztropine | Multiple sclerosis | Myelination | Physiological aspects | Oligodendroglia | Dosage and administration | Drug therapy | Cell differentiation | Cell culture | Dopamine | Drug dosages | Rodents | Cell cycle
Journal Article
Journal Article
Lancet Neurology, ISSN 1474-4422, 2011, Volume 10, Issue 11, pp. 1026 - 1034
Journal Article